308 related articles for article (PubMed ID: 7573017)
1. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis.
Qi Q; Monier-Faugere MC; Geng Z; Malluche HH
Am J Kidney Dis; 1995 Oct; 26(4):622-31. PubMed ID: 7573017
[TBL] [Abstract][Full Text] [Related]
2. Effect of CAPD and hemodialysis on parathyroid function.
Malberti F; Corradi B; Imbasciati E
Adv Perit Dial; 1996; 12():239-44. PubMed ID: 8865912
[TBL] [Abstract][Full Text] [Related]
3. Relationship between the serum parathyroid hormone and magnesium levels in continuous ambulatory peritoneal dialysis (CAPD) patients using low-magnesium peritoneal dialysate.
Cho MS; Lee KS; Lee YK; Ma SK; Ko JH; Kim SW; Kim NH; Choi KC
Korean J Intern Med; 2002 Jun; 17(2):114-21. PubMed ID: 12164088
[TBL] [Abstract][Full Text] [Related]
4. Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH.
Torres A; Lorenzo V; Hernández D; Rodríguez JC; Concepción MT; Rodríguez AP; Hernández A; de Bonis E; Darias E; González-Posada JM
Kidney Int; 1995 May; 47(5):1434-42. PubMed ID: 7637272
[TBL] [Abstract][Full Text] [Related]
5. Serum magnesium concentration is an independent predictor of parathyroid hormone levels in peritoneal dialysis patients.
Navarro JF; Mora C; Macia M; Garcia J
Perit Dial Int; 1999; 19(5):455-61. PubMed ID: 11379859
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of bone mineral density in CAPD patients with dual energy X-ray absorptiometry.
Pasadakis P; Thodis E; Mourvati E; Euthimiadou A; Margaritis D; Manavis J; Vargemezis V
Adv Perit Dial; 1996; 12():245-9. PubMed ID: 8865913
[TBL] [Abstract][Full Text] [Related]
7. Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH.
Coen G; Ballanti P; Bonucci E; Calabria S; Costantini S; Ferrannini M; Giustini M; Giordano R; Nicolai G; Manni M; Sardella D; Taggi F
Nephron; 2002 May; 91(1):103-11. PubMed ID: 12021526
[TBL] [Abstract][Full Text] [Related]
8. The sigmoidal parathyroid hormone-ionized calcium curve and the set point of calcium in hemodialysis and continuous ambulatory peritoneal dialysis.
Malberti F; Corradi B; Pagliari B; Romanini D; Gazo A; Sidoti A; Baretta A; Bellazzi R; Imbasciati E
Perit Dial Int; 1993; 13 Suppl 2():S476-9. PubMed ID: 8399645
[TBL] [Abstract][Full Text] [Related]
9. Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD.
Salusky IB; Ramirez JA; Oppenheim W; Gales B; Segre GV; Goodman WG
Kidney Int; 1994 Jan; 45(1):253-8. PubMed ID: 8127016
[TBL] [Abstract][Full Text] [Related]
10. Low turnover bone disease is the more common form of bone disease in CAPD patients.
Rodriguez-Perez JC; Plaza C; Torres A; Vega N; Anabitarte A; Fernandez A; Lorenzo V; Hortal L; Palop L
Adv Perit Dial; 1992; 8():376-80. PubMed ID: 1361827
[TBL] [Abstract][Full Text] [Related]
11. Intact PTH combined with the PTH ratio for diagnosis of bone turnover in dialysis patients: a diagnostic test study.
Herberth J; Branscum AJ; Mawad H; Cantor T; Monier-Faugere MC; Malluche HH
Am J Kidney Dis; 2010 May; 55(5):897-906. PubMed ID: 20347512
[TBL] [Abstract][Full Text] [Related]
12. Parathyroid hormone variability parameters for identifying high turnover osteodystrophy disease in hemodialysis patients: an observational retrospective cohort study.
De Paola L; Coppolino G; Bolignano D; Buemi M; Lombardi L
Ther Apher Dial; 2010 Dec; 14(6):566-71. PubMed ID: 21118364
[TBL] [Abstract][Full Text] [Related]
13. Reversal of adynamic bone disease by lowering of dialysate calcium.
Haris A; Sherrard DJ; Hercz G
Kidney Int; 2006 Sep; 70(5):931-7. PubMed ID: 16837920
[TBL] [Abstract][Full Text] [Related]
14. K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients.
Barreto FC; Barreto DV; Moysés RM; Neves KR; Canziani ME; Draibe SA; Jorgetti V; Carvalho AB
Kidney Int; 2008 Mar; 73(6):771-7. PubMed ID: 18185506
[TBL] [Abstract][Full Text] [Related]
15. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
16. New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels.
Gal-Moscovici A; Popovtzer MM
Clin Nephrol; 2005 Apr; 63(4):284-9. PubMed ID: 15847255
[TBL] [Abstract][Full Text] [Related]
17. [Renal osteodystrophy in dialysis patients as estimated by three-point bone densitometry].
Kucharska E; Stompór T; Sułowicz W; Drozdz M; Kaczmarczyk I; Szymczakiewicz-Multanowska A; Chruściel B; Kraśnicka M
Przegl Lek; 2000; 57(6):334-9. PubMed ID: 11107868
[TBL] [Abstract][Full Text] [Related]
18. The assay of the hypocalcemic PTH fragment inhibitor with PTH provides a more accurate assessment of renal osteodystrophy compared to the intact PTH assay.
Cantor T; Sci B
Nefrologia; 2003; 23 Suppl 2():69-72. PubMed ID: 12778858
[TBL] [Abstract][Full Text] [Related]
19. Low- and high-turnover bone disease in continuous ambulatory peritoneal dialysis: effects of low-Ca2+ peritoneal dialysis solution.
Carozzi S; Nasini MG; Santoni O; Pietrucci A
Perit Dial Int; 1993; 13 Suppl 2():S473-5. PubMed ID: 8399644
[TBL] [Abstract][Full Text] [Related]
20. Serum markers of low-turnover bone disease in Mexican children with chronic kidney disease undergoing dialysis.
Avila-Díaz M; Matos M; García-López E; Prado MD; Castro-Vázquez F; Ventura MD; González E; Amato D; Paniagua R
Perit Dial Int; 2006; 26(1):78-84. PubMed ID: 16538879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
